Showing results (1661-1670 of 19,551) with videos related to
Sort By:
Pageof 1,956
BMC Cancer|September 27, 2007
Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancerJack X Yu, Anieta M Sieuwerts, Yi Zhang, et al.BMC Cancer|August 1, 2007
Induction of plasminogen activator inhibitor type-1 (PAI-1) by hypoxia and irradiation in human head and neck carcinoma cell linesDaniela Schilling, Christine Bayer, Anneke Geurts-Moespot, et al.BMC Cancer|August 3, 2006
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trialSandro Pignata, Giovanni Scambia, Antonella Savarese, et al.BMC Cancer|July 28, 2006
Increased tartrate-resistant acid phosphatase (TRAP) expression in malignant breast, ovarian and melanoma tissue: an investigational studyA Honig, L Rieger, M Kapp, et al.BMC Cancer|October 20, 2006
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancerEdward R Sauter, Wenyi Qin, Lisa Schlatter, et al.BMC Cancer|September 2, 2006
Gene x Gene interaction between MnSOD and GPX-1 and breast cancer risk: a nested case-control studyDavid G Cox, Rulla M Tamimi, David J HunterBMC Cancer|July 1, 2006
Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast diseaseLisa Gallicchio, Sonja I Berndt, Meghan A McSorley, et al.BMC Cancer|July 12, 2008
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancerLászló Herszényi, Fabio Farinati, Romilda Cardin, et al.BMC Cancer|July 4, 2008
Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapyMasashi Ishikawa, Takayuki Miyauchi, Yutaka KashiwagiBMC Cancer|July 4, 2008
TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformationMichael D Oberst, Stacey J Beberman, Liu Zhao, et al.Pageof 1,956